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Abstract
Background: Human papillomavirus (HPV) is a causative factor for tonsillar squamous cell carcinoma (TSCC) and patients
with HPV positive (HPV
+) TSCC have a better clinical outcome than those with HPV negative (HPV
2) TSCC. However, since
not all patients with HPV
+TSCC respond to treatment, additional biomarkers are needed together with HPV status to better
predict response to therapy and to individualize treatment. For this purpose, we examined whether the number of tumor
infiltrating cytotoxic and regulatory T-cells in TSCC correlated to HPV status and to clinical outcome.
Methods: Formalin fixed paraffin embedded TSCC, previously analysed for HPV DNA, derived from 83 patients, were divided
into four groups depending on the HPV status of the tumor and clinical outcome. Tumors were stained by
immunohistochemistry and evaluated for the number of infiltrating cytotoxic (CD8
+) and regulatory (Foxp3
+) T-cells.
Results: A high CD8
+ T-cell infiltration was significantly positively correlated to a good clinical outcome in both patients
with HPV
+ and HPV
- TSCC patients. Similarly, a high CD8
+/Foxp3
+ TIL ratio was correlated to a 3-year disease free survival.
Furthermore, HPV
+TSCC had in comparison to HPV
2TSCC, higher numbers of infiltrating CD8
+ and Foxp3
+ T-cells.
Conclusions: In conclusion, a positive correlation between a high number of infiltrating CD8
+ cells and clinical outcome
indicates that CD8
+ cells may contribute to a beneficial clinical outcome in TSCC patients, and may potentially serve as
a biomarker. Likewise, the CD8
+/Foxp3
+cell ratio can potentially be used for the same purpose.
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Introduction
Recent studies from Europe and the US have reported an
increase in the incidence of oropharyngeal squamous cell
carcinoma (OSCC), particularly for tonsillar squamous cell
carcinoma (TSCC). This increase has been attributed to an
increased prevalence of human papillomavirus (HPV) infection
[1,2,3,4]. Accordingly, a 7-fold increase in HPV-positive (HPV
+)
TSCC, in parallel to a decline in HPV-negative (HPV
2) TSCC
has been demonstrated for patients in Stockholm, Sweden, the last
three decades [3] and a similar trend has been demonstrated in the
US [2]. Importantly also, HPV has been shown to be a favorable
prognostic factor for patients with OSCC including TSCC
[5,6,7,8]. However, not all patients with HPV
+TSCC fare well
and thus, although HPV by itself is an important prognostic
marker, additional biomarkers are needed in TSCC to better
predict treatment response before individualized treatment can be
implemented in clinical practice.
It has been suggested that HPV
+ and HPV
2TSCC are two
different tumor disease entities with different tumor and patient
characteristics. Whereas HPV associated tumors, including
HPV
+TSCC are driven by viral oncogenes, e.g. E6 and E7, and
have fewer cellular mutations, HPV
2TSCC develop by accumu-
lation of genetic changes mainly caused by environmental factors
such as smoking [9]. As foreign antigens, E6 and E7 may act as
potential targets for an immune response against HPV induced
tumors and in vitro studies have shown that T-cells isolated from
HPV
+ cervical cancer can recognize and kill E6 and E7 expressing
tumor cells [10]. Moreover, tumor specific T-cells are detected in
most cervical cancer patients, although at low and insufficient
levels [11,12] and the presence of tumor infiltrating lymphocytes
(TILs) has been linked to a better prognosis [13,14]. This has also
been observed for other tumor types with no known viral
association [15,16]. However, TILs may act as a double-edged
sword. While a pronounced infiltration of CD8
+ lymphocytes has
been linked to a favorable prognosis in many malignancies, the
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38711role of infiltrating T regulatory cells (Tregs) (often defined as
Foxp3
+ lymphocytes) is often the reverse [17]. Tregs may promote
tumor progression, and increased levels of Tregs have been
observed in patients with a variety of tumors and linked to a worse
prognosis [18,19], although there are exceptions where Treg
infiltration has been linked to a favorable prognosis [20,21].
Nevertheless, the role of infiltrating CD8
+ and Foxp3
+ lympho-
cytes has, to our knowledge, not been investigated in TSCC in
correlation to patient outcome and HPV status.
The purpose of this study was to examine the presence of tumor
infiltrating CD8
+ and Foxp3
+ T-cells in TSCC in relation to
clinical outcome and tumor HPV status, and to establish if these
TILs can potentially be used in the clinic as biomarkers either
alone, or together with the HPV status of the tumor to predict
clinical outcome.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee at
Karolinska Institutet, Stockholm, Sweden, according to the ethical
permissions 2005/431-31/4, 2005/1330-32 and 2009/1278-31/4.
Written informed consent was obtained from all participants in the
study.
Patients and Material
The cohort consisted of all patients, diagnosed 2000–2006 with
TSCC (ICD-10 C09.0-9), that were treated with the intention to
cure at Karolinska University Hospital, Stockholm, Sweden, and
had available pre-treatment paraffin embedded tumor biopsies.
Treatment consisted of accelerated radiotherapy
(RT)(1.1+2.0 Gy/day for 4.5 weeks, total dose: 68 Gy) or
conventional RT (2.0 Gy/day, for 6.5–7 weeks, total dose:
68 Gy) or, in four cases, induction chemotherapy followed by
concomitant RT (CRT). After treatment, patients were followed-
up by clinical examination every 3 months during the first 2 years
and every 6 months the 3rd year.
Data on the presence of high risk HPV types (presence of HPV
DNA by PCR) and p16
INK4a status (by immunohistochemistry)
were obtained from previous studies [3,7,22] and patients were
divided into 4 groups (A-D) at baseline (for further details see
Tables 1 and 2); (A) a random sample (n=31) of all patients
(n=109) with HPV
+, p16
INK4a positive (.75% p16
INK4a positive
tumor cells) (p16
+) tumors with a good clinical outcome (defined as
no relapse and alive 3 years after diagnosis); (B) all patients (n=21)
with HPV
+, p16
+ tumors with a poor clinical outcome (defined as
relapsed in disease and/or dead of disease within 3 years after
diagnosis); (C) all patients (n=11) with HPV
2, p16
INK4a negative
(p16
2) tumors with a good clinical outcome; (D) all patients
(n=20) with HPV
2, p16
2 tumors with a poor clinical outcome
(Table 1). A sample of 31 of the 109 original tumors in group A
was chosen to obtain a more similar number of patients from each
group for further studies of TILs, since this group dominated with
68% of the total number of tumors. Patients with HPV
+, p16
2
(n=17) and HPV
2, p16
+ tumors (n=4) were excluded from
further analysis to obtain homogenous groups and to only include
Table 1. Characteristics of patients and tumors included in the study.
Group A Group B Group C Group D
HPV
+ good
1 HPV
+ poor
1 HPV
2 good
1 HPV
2 poor
1
Total 31 21 11 20
n% n% n% n%
Sex
male 21 68% 15 71% 9 82% 17 85%
female 10 32% 6 29% 2 18% 3 15%
Age (years)
mean 56.1 62.3 60.9 64.4
median 56 62 59 61.5
Stage
I 0 0% 0 0% 4 36% 0 0%
II 2 6% 1 5% 2 18% 1 5%
III 13 42% 8 38% 2 18% 5 25%
IV 16 52% 12 57% 3 27% 14 70%
Differentiation
low 20 65% 14 67% 6 55% 9 45%
medium 11 35% 6 29% 5 45% 8 40%
high 0 0% 1 5% 0 0% 3 15%
Treatment
RT
2 31 100% 20 95% 11 100% 20 100%
CRT
2 00 % 15 % 00 % 00 %
1Good and poor denote clinical outcome.
2Abbreviations: RT, radiotherapy; CRT, chemoradiotherapy.
doi:10.1371/journal.pone.0038711.t001
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+ TSCC expressing HPV E6/E7, since p16
INK4a expression
in HPV
+ tumors is considered an indication of E7 expression [23].
Patients dying of other causes than TSCC were also excluded. All
HPV
+ TSCC were HPV16
+ with exception of one tumor with
HPV33 and one with HPV56.
Immunohistochemistry
A standard streptavidin-biotin peroxidase method was em-
ployed on 4 mm formalin fixed, paraffin embedded, sections using
the mouse monoclonal antibodies anti-CD8 (dilution, 1:40; clone
4B11; Novocastra Laboratories) and anti-Foxp3 (dilution 1:100,
clone 236A/E7; eBioscience). All sections were subsequently
incubated with biotinylated secondary anti-mouse antibody
(1:200, Vector Laboratories, Burlingame, CA, U.S.A.) followed
by incubation with the avidin-biotin-complex-PO using the
VECTASTATINH EliteH ABC kit (Vector Laboratories) and
developed in DAB.
The CD8
+ and Foxp3
+ tumour lymphocyte infiltration was
evaluated by two researchers, blinded for clinical outcome, each
counting the cells in 10 randomly selected high-power fields (406)
per sample. The mean value was reported for each tumor. The
ratio of tumor infiltrating CD8
+ and Foxp3
+ cells was calculated
for each individual tumor, the mean of these ratios was then
calculated per subgroup.
Statistical Analysis
Tests for comparisons of continuous data were performed using
linear regression models. Results were presented as mean
differences or odds-ratios together with 95% confidence interval.
The comparisons of patient and tumor characteristics between the
different groups in Tables 1 and 2 were performed using Fisher’s
exact test (two-tailed). All these analysis were performed in the
STATA11 (StataCorp). A p-value#0.05 was considered as
significant.
Table 2. Study sample and all patients with HPV
+TSCC and
a good clinical outcome, diagnosed in Stockholm between
2000–2006.
Sample All patients
n=31 n=109
n% n %
Sex
male 21 68% 84 77%
female 10 32% 25 23%
Stage
I 00 % 1 1 %
II 26 % 9 8 %
III 13 42% 36 33%
IV 16 52% 63 58%
Differentiation
low 20 65% 71 65%
medium 11 35% 37 34%
high 00 % 1 1 %
Treatment
RT
1 31 100% 106 97%
CRT
1 00 % 3 3 %
Age (years)
mean 56.1 58.2
median 56 57
1Abbreviations: RT, radiotherapy; CRT, chemoradiotherapy.
doi:10.1371/journal.pone.0038711.t002
Figure 1. Examples of TSCC stained for tumor infiltrating CD8
+ and Foxp3
+ cells. TSCC with (A) low and (B) high CD8
+ infiltration and (C)
low and (D) high Foxp3
+ infiltration.
doi:10.1371/journal.pone.0038711.g001
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diagnosis to the date of the last known occasion that the patient
was disease-free or the date of disease recurrence (local, regional or
distant recurrence). Death without documented recurrence was
censored at the date of death. Kaplan-Meier curves were used to
present survival data and the log-rank test was used to compare
survival curves. In the multivariate analyze, a Cox proportional
hazards model was used to adjust for covariates. Two-sided p-
values were reported. These analyses were performed in SPSS
(IBM SPSS Statistics, v20).
Results
Clinical and Pathological Parameters of Patients and
Tumors
Details of all patients and their tumors are shown in Tables 1
and 2. As described above, patients were divided into 4 study
groups depending on tumor HPV status and clinical outcome
within 3 years. The only significant difference between the
different study groups was that patients with HPV
2tumors and
good clinical outcome had a lower clinical stage than patients with
poor clinical outcome (p=0.005).
There were no differences with regard to any of the studied
clinical parameters between the sample of 31 patients and the total
population of 109 patients with HPV
+ TSCC and good clinical
outcome (Table 2).
The Number of CD8
+ TILs Correlates to HPV Status and
Clinical Outcome for Patients with TSCC
TSCC patients with a good clinical outcome had a signifi-
cantly higher number of CD8
+ TILs in their tumors (Figure 1),
than those with poor clinical outcome, independent of tumor
HPV status (mean 50.4 and 12.8 resp., p,0.001), (Table 3 and
Figure 2A). Furthermore, when stratifying for HPV status,
HPV
+TSCC, from patients with a good clinical outcome, had
more CD8
+ TILs than those from patients with poor clinical
outcome (mean 61.4 and 21.0 resp., p=0.002), (Table 3). The
mean number of CD8
+ TILs was also significantly higher in
HPV
2TSCC from patients with good clinical outcome, when
compared to HPV
2TSCC from patients with poor clinical
outcome (mean 19.4 and 4.7 resp., p=0.001).
Moreover, HPV
+TSCC had a significantly higher mean
number of tumor infiltrating CD8
+ lymphocytes compared to
HPV
2TSCC (mean 45.6 and 9.9 resp., p,0.001) (Figure 2A).
This difference was still significant when adjusted for prognosis
(p=0.001).
To study the correlation between CD8
+ TILs and DFS in
HPV
+ TSCC patients, a Kaplan-Meier analysis was performed.
HPV
+ and HPV
-TSCC patients were dichotomized based on the
median value (33 and 4.4 respectively) of CD8
+ TILs. As
demonstrated in Figure 3A patients with HPV
+ tumors and a high
number of CD8
+ TIL had a cumulative survival of 84% compared
to 55% for patients with low number of CD8
+ (p=0.02). Similar
cumulative survival trends (64% and 36%, respecitvely) were also
observed for HPV
- patients, although these differences were not
statistically significant (Figure 3B). Notably, for patients with
HPV
+TSCC the Kaplan-Meier curves were calculated on the
sample of TSSC belonging to group A and all TSCC from group
B (Figure 3A).
The Number of Foxp3
+ TILs Correlates to HPV Status in
TSCC
A significantly higher number of Foxp3
+ TILs (Figure 1) were
observed in HPV
+TSCC as compared to that in HPV
2TSCC
(mean 33.2 and 14.7, resp., p,0.001) (Figure 2B). When adjusting
for prognosis, this difference was still significant (p=0.001).
However, no differences in the levels of Foxp3
+ TILs were
observed in tumors from patients with a good or poor clinical
outcome (mean 27.9 and 24.6, resp.) (Table 3).
A High CD8
+/Foxp3
+ Ratio is Linked to a Good Clinical
Outcome in Patients with TSCC
As a measurement of the relative number of cytotoxic and
regulatory T-cells in the tumors, the ratio of tumor infiltrating
Table 3. Number of Foxp3
+ and CD8
+ T-cells and CD8
+/Foxp3
+ cell ratio by clinical outcome and tumor HPV status.
Clinical outcome Unadjusted effects
b Effects
b adjusted for HPV status
Factor HPV status
a Good (n=42) Poor (n=41) Mean difference (95% CI) P-value
c Mean difference (95% CI) P-value
c
Mean CD8
+ TIL value Positive 61.4 (31) 21.0 (21) 40.4 (15.8 to 65.0) 0.002
Negative 19.4 (11) 4.7 (20) 14.7 (6.2 to 23.1) 0.001
0.12
d
Total 50.4 (42) 12.8 (41) 37.6 (21.3 to 53.8) ,0.001 30.9 (15.1 to 46.7) ,0.001
Mean Foxp3
+ TIL value Positive 33.7 (31) 32.5 (21) 1.2 (216.0 to 18.4) 0.89
Negative 11.6 (11) 16.4 (20) 24.7 (212.2 to 21.6) 0.57
0.65
d
Total 27.9 (42) 24.6 (41) 3.3 (29.2 to 15.8) 0.60 20.95 (213.3 to 11.4) 0.88
Mean CD8
+/Foxp3
+ ratio Positive 3.0 (31) 1.6 (21) 1.4 (20.4 to 3.1) 0.13
Negative 8.2 (11) 1.1 (20) 7.0 (21.5 to 15.6) 0.10
0.10
d
Total 4.3 (42) 1.4 (41) 3.0 (20.3 to 6.2) 0.07 3.5 (0.15 to 6.8) 0.04
aHPV data obtained from previous studies (3, 6, 25).
bEffects of HPV-status (negative versus positive) estimated using linear regression.
cP-values refers to F-tests.
dOverall test for effect modification (i.e. interaction between HPV status and clinical outcome).
doi:10.1371/journal.pone.0038711.t003
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+ and Foxp3
+ cells for different groups of TSCC. A) number of CD8
+ TILs, B) number
Foxp3
+TILsandC)theCD8
+/Foxp3
+cellratio.‘‘Good’’and‘‘poor’’denotesclinicaloutcome.InadditiontothefourTSCCgroupsdefinedintheMethods
section,differentcombinationsofgroupshavealsobeencompared.Thus,‘‘HPV
+good’’correspondstogroupA;‘‘HPV
+poor’’togroupB;‘‘HPV
2good’’
to group C; ‘‘HPV
2 poor’’ to group D; HPV
+ to groups A+B, HPV
2 to groups C+D; ‘‘good’’ to groups A+C; and ‘‘poor’’ to groups B+D. In order to better
visualize the details in the lower part of Figure 1C the upper part of the diagram including the upper whisker (at a ratio of 80) was omitted.
doi:10.1371/journal.pone.0038711.g002
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+ and Foxp3
+ cells was calculated for each tumor. A high
CD8
+/Foxp3
+ cell ratio is an indication that the regulatory T-cells
are in a minority and thus less likely to overshadow the function of
cytotoxic T-cells. For patients with TSCC a high CD8
+/Foxp3
+
ratio was positively correlated to a good clinical outcome when
adjusted for prognosis (p=0.04) (Table 3). However, the difference
related to prognosis in CD8
+/Foxp3
+ TIL ratio was not significant
when patients with HPV
+TSCC or HPV
2TSCC were analyzed
separately, although the tendency was similar to that observed for
TSCC patients in general.
To study the correlation between a high/low CD8
+/Foxp3
+
TIL ratio and DFS for TSCC, a Kaplan-Meier analysis was
performed. HPV
2 and HPV
+TSCC patients were dichotomized
based on a CD8
+/Foxp3
+ TIL ratio above or below 1. As
demonstrated in Figure 3D patients with HPV
2TSCC and a high
CD8
+/Foxp3
+ TIL ratio had a cumulative survival of 73% as
compared to 28% for patients with a low CD8
+/Foxp3
+ TIL ratio
(p=0.03). Similarly, HPV
+TSCC patients with a high CD8
+/
Foxp3
+ TIL ratio had a higher cumulative survival (82%) than
those with a low CD8
+/Foxp3
+ TIL ratio (54%, p=0.04)
(Figure 3C).
Correlation between Clinical Parameters, CD8
+ and
Foxp3
+ Cells and 3-year DFS in Patients with TSCC
When CD8
+ and Foxp3
+ TILs values for all TSCC, stratified
for HPV status, were analyzed for age, sex or clinical stage, no
correlation was found (data not shown).
Hazard ratios (HR) were calculated separately for HPV
+ and
HPV
2TSCC, using both univariate and multivariate tests
(Table 4). For HPV
+TSCC the hazard ratio for a high number
Figure 3. Kaplan-Meier curves showing disease free patient survival depending on TSCC HPV status and TILs, and n denotes the
number of patients in each stratified group. A) HPV
+TSCC and B) HPV
2TSCC patients stratified by the number of CD8
+ TILs. High and low
denotes CD8
+ TIL count above and below the median values of 33 for HPV
+TSCC and 4.4 HPV
2TSCC. C) HPV
+TSCC and D) HPV
2TSCC patients
stratified by the ratio of CD8
+/FoxP3
+ cell ratio. High and low denotes CD8
+/FoxP3
+ cell ratio above and below 1.
doi:10.1371/journal.pone.0038711.g003
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+ cells was 0.27 (p=0.029), while for HPV
2TSCC the
hazard ratio for a high CD8
+/Foxp3
+ ratio was 0.27 (p=0.048).
To determine whether CD8
+ cells and CD8
+/Foxp3
+ ratio were
independent prognostic factors, a multivariate Cox analysis was
performed with clinical stage, age and sex as covariates (Table 4).
For HPV
+TSCC, both the number of CD8
+ cells and age were
independently significantly correlated to 3-year DFS (p=0.034
and p=0.009, resp.). For HPV
2TSCC both CD8
+/Foxp3
+ ratio
and stage was significantly independently correlated to 3-year DFS
(p=0.023 and p=0.039, resp.). Similarly, a high CD8
+/Foxp3
+
ratio correlated to a 3-year DFS both in the univariate and
multivariate analyzes also for HPV
+TSCC (HR 0.33, p=0.048
and HR 0.23, p=0.015 respectively) (data not shown).
Discussion
In this study, we found a significant correlation between a high
CD8
+ T-cell infiltration and clinical outcome for both patients
with HPV
+ and HPV
2TSCC, as well as between a high CD8
+/
Foxp3
+ TIL ratio and disease free survival for both patients with
HPV
+ and HPV
2TSCC. In addition, we demonstrated a correla-
tion both between tumor infiltrating CD8
+ and Foxp3
+ T-cells to
HPV status in TSCC.
The fact that CD8
+ infiltration was more pronounced and
influenced prognosis positively in this study for HPV
+TSCC, may
be an important reason for why the majority of HPV
+TSCC have
a good clinical outcome in comparison to HPV
2TSCC [6,7]. This
would be in line with experimental studies showing the importance
of the immune system for combating HPV
+ head and neck
squamous cell carcinoma (HNSCC) [24]. The result is also in
concordance with many studies on tumors from other sites e.g. for
colon and cervical cancer [13,14,15,18]. Notably, in cervical
cancer, where the vast majority of tumors are HPV
+, both a high
number of CD8
+ TIL and a high CD8
+/regulatory T-cell ratio
were correlated to the absence of lymph node metastasis [14]. A
similar result has also been published for HNSCC, where Ogino
and colleagues demonstrate a positive correlation between a high
CD8
+ T-cell infiltration and cause specific survival [25]. In
addition, the presence of HPV16 specific T-cells in HPV
+
HNSCC was recently demonstrated, although correlation to
prognosis was not investigated [26]. The strong positive correla-
tion between CD8
+ TILs and good clinical outcome for patients
with TSCC indicates that assessment of CD8
+ TILs could be used
as an additional prognostic biomarker in combination with tumor
HPV status.
We also demonstrated that a high CD8
+/Foxp3
+ T-cell ratio
significantly correlated to a disease free survival in both patients
with HPV
+ and HPV
2TSCC. Previous publications have linked
Foxp3
+ TILs to a worse prognosis in e.g. ovarian and breast
cancer [16,18]. Furthermore, a high percentage of Tregs has been
correlated to a poor 5-year survival in cervical cancer [27].
However, there are also instances where Foxp3
+ TILs have been
linked to a favorable prognosis such as e.g. in colon cancer,
Hodgkin lymphoma and HNSCC [20,21,28]. The result obtained
in the present study indicates that infiltrating T-cells also are of
importance for clinical outcome for patients with HPV
2TSCC,
although possibly to a lesser extent. The assessment of CD8
+/
Foxp3
+ T-cell ratio could thus also be used as a clinical prognostic
marker for patients with HPV
+ or HPV
2TSCC.
Importantly, estimating CD8
+ and Foxp3
+ TILs by IHC can be
performed at pathology units in hospitals. The HPV status of
TSCC is already assessed routinely in some clinics, e.g. at the
Karolinska University Hospital in Stockholm, and if used in
conjunction with evaluation of CD8
+ and Foxp3
+ TILs in
pathology units, a better prediction of clinical outcome may be
obtained. However, the size of the field evaluated and cut-off
values have to be precisely defined.
In addition, we observed that HPV
+TSCC had a significantly
higher infiltration of both CD8
+ and Foxp3
+ cells than
HPV
2TSCC. This was not unexpected given that HPV
+TSCC
expresses foreign viral antigens. In fact, the data indicate that,
although the immune defense has failed to impede the de-
velopment of the HPV
+TSCC, there is still an immunological
difference between HPV
+ and HPV
2TSCC.
It is important to note that the presence of TILs in TSCC is not
enough for tumor rejection. However, it has been demonstrated in
a mouse model that an intact immune defense is important for
a complete tumor clearance upon radiation treatment [24].
Furthermore, it is possible that irradiation may activate the
immune response both against remaining viable cells of the
original tumor and against lymph node metastasis.
Recently, many tumor biomarkers have been explored with
regard to prognosis for patients with HNSCC [29,30,31,32].
However, in most of these studies the HPV status of the tumors
was not taken into account and often tumors from different
HNSCC subsites were grouped together when biomarkers were
correlated to prognosis. The results of the present study
demonstrate the importance of separating tumors depending on
HPV status. In addition, in studies of this kind, the tumors should
also be stratified depending on tumor subsite, since e.g. the overall
survival for patients with HNSCC differs depending on both HPV
status and tumor subsite.
There are some limitations in the present study. Firstly, it is
a retrospective study with all patients diagnosed with TSCC in
Stockholm during 2000–2006 and treated with intention to cure.
However, it is important to note that treatment during this period
was standardized with conventional/accelerated RT. In addition,
previous publications, analyzing the clinical outcome of the
patients included in the present study, have failed to demonstrate
differences in clinical outcome for patients with oropharyngeal
cancers depending on treatment [33,34].
Secondly, most TSCC today are HPV
+ with a favorable clinical
outcome for the patients. Hence, this group was reduced in the
present study by randomization. On the other hand, we were not
able to demonstrate any significant differences between the study
sampleandthetotalmaterialinthisgroup.Anotherlimitationisthe
Table 4. Univariate and multivariate analyses of progonostic
factors for 3-year disease free survival in patients with TSCC.
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
HPV
+TSCC
CD8
+ 0.27 (0.09–0.88) 0.029 0.28 (0.084–0.91) 0.034
stage 0.85 (0.11–6.48) 0.88 1
age 5.5 (1.55–19.6) 0.008 5.58 (1.5–20.4) 0.009
sex 0.83 (0.27–2.62) 0.75 0.68 (0.21–2.22) 0.52
HPV
-TSCC
CD8
+/Foxp3
+ 0.27 (0.073–0.99) 0.048 0.21 (0.057–0.81) 0.023
stage 6.91 (0.89–53.6) 0.064 8.9 (1.12–70.6) 0.039
age 0.74 (0.23–2.4) 0.62 0.64 (0.18–2.31) 0.50
sex 1.08 (0.56–2.05) 0.83 0.92 (0.46–1.87) 0.83
Abbreviations: HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0038711.t004
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2 groups, although all patients
were included with this feature. To better study the HPV
2TSCC
population, other medical centers should be included.
Finally, we have not assessed if the tumor infiltrating CD8
+ and
Foxp3
+ cells are targeted against specific tumor associated antigens
or assayed for functional CD8
+ using e.g. granzyme B. Further-
more, since Foxp3, although at low levels, may be transiently
induced in CD4
+ and CD8
+ T-cells upon stimulation, all Foxp3
+
TILs may not be Tregs [35]. However, for the purpose of this
study, i.e. to find clinically relevant and easily identifiable markers,
this was not of importance, although it would be of interest to
address these questions in other studies.
In conclusion, tumor infiltrating CD8
+ and Foxp3
+ cells in
TSCC display different profiles depending on tumor HPV status
and clinical outcome. Thus, combining the presence of CD8
+ T-
cells and/or CD8
+/Foxp3
+ cell ratio with HPV status, may be of
additive prognostic value and for better individualizing patient
treatment.
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